Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo

Kidney International

Volumn 58, Issue 3, 2000, Pages 1219-1227

  Brown, N J ^a   Nakamura, S ^a   Ma, L ^a   Nakamura, I ^a   Donnert, E ^a   Freeman, M ^a   Vaughan, D E ^a   Fogo, A B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Fibrosis; Nephrosclerosis; Progressive renal disease; Renal injury; Renin; Spironolactone

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY INJURY; MALE; NEPHROSCLEROSIS; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RADIATION INJURY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0033849916     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00277.x     Document Type: Article

References (37)

1. Glomerular actions of angiotensin II
2. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in rat
3. Renal injury from angiotensin II-mediated hypertension
4. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms
5. Internephron heterogeneity of growth factors and sclerosis-modulation of platelet derived growth factor by angiotensin II
6. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control
7. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
8. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney
9. The effects of intravenous infusions of valine-5 angiotensin II and other pressor agents on urinary electrolytes and corticoids including aldosterone
10. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis
11. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension
12. Role of aldosterone in the remnant kidney model in the rat
13. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism
14. Mineralocorticoid blockade reduces vascular injury in strokeprone hypertensive rats
15. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats
16. Cell-associated plasminogen activation: Regulation and physiologic functions
17. Proteinases and extracellular matrix remodeling
18. The plasminogen activator/ plasmin system
19. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
20. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells
21. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells
22. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
23. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production
24. Effect of activation and inhibition of the reninangiotensin system on plasma PAI-1 in humans
25. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
26. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome
27. Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis
28. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
29. Vascular permeability and late radiation fibrosis in mouse lung
30. Treatment of radiation nephropathy with captopril
31. Three new epoxy-spirolactone derivatives: Characterization in vivo and in vitro
32. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats
33. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta
34. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit
35. Angiotensin II- and angiotensin III-induced aldosterone release in vivo in the rat
36. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin